Angitia Biopharmaceuticals
PrivateLast Round
Series D
Feb 5, 2026
Total Funding Raised
$406M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Angitia Biopharmaceuticals is a biotechnology company that discovers and develops innovative biologic therapies for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta, and spinal fusion.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Angitia Biopharmaceuticals Comparables
Compare Angitia Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DiscGenics | 82% | |
| Transcenta Holding | 78% | |
| Mesentech Inc. | 78% |
Angitia Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Feb 5, 2026 | ||||
| Series C | Dec 11, 2024 | ||||
| Series B Extension | Jan 1, 2024 | ||||
| Series B Extension | Oct 25, 2023 | ||||
| Series B | Oct 31, 2021 | ||||
Series A | Aug 18, 2020 |
Key People
Founding team and executive leadership
Angitia Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed Asia | Series A |
| Bain Capital Life Sciences | Series D, Series C |
| Janus Henderson Group | Series D, Series C |
| RA Capital Management | Series D |
| Oriza Holdings | Series A, Series B, Series B Extension |
| Firstred Capital | Series B |
| Hillhouse Investment | Series D, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 119% MoM.
- May 29, 2026
Osteoporosis and OI programs are in global Phase 2 studies.
Angitia Biopharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Angitia Biopharmaceuticals's valuation, stock price, and market status.
Is Angitia Biopharmaceuticals a public or private company?
Angitia Biopharmaceuticals is a private company.
What is the current stock price of Angitia Biopharmaceuticals?
Angitia Biopharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Angitia Biopharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Angitia Biopharmaceuticals worth (valuation)?
Valuation information for Angitia Biopharmaceuticals is not publicly available.
Can I buy Angitia Biopharmaceuticals stock?
Angitia Biopharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Angitia Biopharmaceuticals's last funding round?
Angitia Biopharmaceuticals's most recent funding round was Series D on February 5, 2026.
Who are the main investors in Angitia Biopharmaceuticals?
Key investors in Angitia Biopharmaceuticals include Bain Capital Life Sciences, Hillhouse Investment, Frazier Life Sciences, Morningside Group, Venrock.
Will Angitia Biopharmaceuticals IPO soon?
No public IPO plans have been announced for Angitia Biopharmaceuticals.
How can I track Angitia Biopharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Angitia Biopharmaceuticals's shares on secondary markets.